All Updates

All Updates

icon
Filter
Partnerships
Tempus partners with Actuate Therapeutics to discover biomarker profiles for Elraglusib
Precision Medicine
Feb 23, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Feb 23, 2023

Tempus partners with Actuate Therapeutics to discover biomarker profiles for Elraglusib

Partnerships

  • AI-driven bioinformatics company Tempus partnered with Acuatate Therapeutics, a New York-based clinical-stage pharmaceutical company, to identify biomarker profiles for patients who benefit from Acutate’s GSK-3β inhibitor elraglusib.

  • Under the terms of the agreement, Tempus will provide its xF+ liquid biopsy panel, a clinical cell-free DNA test, and its DNA methylation test, as part of an ongoing clinical trial to identify patients who will respond to the drug. A phase I/II study will be conducted by Actuate Therapeutics to evaluate elraglusib alone and in combination with chemotherapy in patients that have refractory blood cancers and solid tumors. If successful, this will demonstrate a new way in which precision medicine can be incorporated into clinical development.

  • Actuate is a clinical-stage pharmaceutical company that is currently in the process of developing new treatments for cancer and inflammatory diseases. It has several ongoing studies of elraglusib, including pancreatic cancer, salivary gland carcinoma, myelofibrosis, and pediatric cancers.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.